Immune Medicine in Action: How Adaptive Immunosequencing Helped Validate a Personalized Vaccine Trial in PDAC
Adaptive Immunosequencing provided critical insight into the T-cell response elicited by the vaccine, and its correlation with delayed disease recurrence.
At Adaptive, we know our diagnostic tests provide key information that help physicians and patients make treatment decisions, but we relish the opportunity to speak with them firsthand.
Adaptive recently partnered as a sponsor with trusted community oncology organizations Association of Community Cancer Center (ACCC) and National Community Oncology Association (NCODA) to share vital minimal (or measurable) residual disease (MRD) education with community doctors who treat hematologic oncology.
Clinician Attitudes are Shifting on MRD-guided Decision Making in Multiple Myeloma Allison Jacob, Senior Medical Director, Minimal Residual Disease This September marks four years since the 2018 Food and Drug Administration clearance for clonoSEQ to detect and monitor minimal residual disease (MRD) in bone marrow from patients with acute lymphoblastic leukemia (ALL) and multiple myeloma […]
With the opening of a new corporate headquarters in Seattle’s South Lake Union and expanded offices in South San Francisco and New York City, Adaptive continues to grow its employee base and increase the impact of its immune medicine platform in areas such as infectious diseases, autoimmune conditions, and cancer.